Harmony Biosciences Holdings, Inc.
A biopharmaceutical company in Plymouth Meeting, Pennsylvania, that makes WAKIX (pitolisant), a medication for narcolepsy that helps people with the sleep disorder stay awake and controls sudden muscle weakness (cataplexy). Founded in 2017 by Paragon Biosciences, the company licensed the drug's U.S. rights from the French firm Bioprojet. The brand name WAKIX is a play on the word "wake," and unlike many narcolepsy treatments, it is not a controlled substance.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Vanguard Portfolio Management | 13GPassive | 5.08% | 2.94M | Jul 31, 2026 |
| BlackRock, Inc. | 13G/APassive | 11.3% | 6.53M | Jul 28, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| FMR LLC | 13G/APassive | 5.4% | 3.11M | Feb 5, 2026 |
| Abigail P. Johnson | 13G/APassive | 5.4% | 3.11M | Feb 5, 2026 |
| Antonio J. Gracias | 13G/APassive | 3.2% | 1.83M | Nov 14, 2025 |
| Juan A. Sabater | 13G/APassive | 2.4% | 1.39M | Nov 14, 2025 |
| Valor Equity Associates IV L.P. | 13G/APassive | 2.2% | 1.27M | Nov 14, 2025 |
| Valor Equity Capital IV LLC | 13G/APassive | 2.2% | 1.27M | Nov 14, 2025 |
| Valor Management L.P. | 13G/APassive | 2.2% | 1.30M | Nov 14, 2025 |